EI
DNTH icon

Ethic Inc’s Dianthus Therapeutics DNTH Stock Holding History

Ethic Inc’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$277K Buy
+3,300
New +$191K ﹤0.01% 1059
2025
Q4 		– Sell
-5,530
Closed -$218K – 1226
2025
Q3 		$218K Buy
+5,530
New +$141K ﹤0.01% 1091

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ethic Inc's DNTH Position: Q1 2026 in Review

Ethic Inc opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 3,300 shares worth $277K. The stake represents ﹤0.01% of the portfolio and ranks #1059 among its holdings. This is a return to the name: Ethic Inc previously reported a position in DNTH as recently as Q3 2025.

Ethic Inc first reported a position in DNTH in Q3 2025 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Ethic Inc held 3,300 shares of Dianthus Therapeutics worth $277K as of Q1 2026.
  • Dianthus Therapeutics was a new Ethic Inc position in Q1 2026.
  • Dianthus Therapeutics made up ﹤0.01% of Ethic Inc's portfolio in Q1 2026, its #1059 holding.
  • Ethic Inc first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Ethic Inc's 13F filing for Q1 2026, filed 27 Apr 2026.